Sunday 11 October 2026
Export all ABBV data to Excel Powerpack
AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
276.47
4.05
+1.49%
Follow ABBV
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (208.10%) | (139.61%) | 6,155.88% | 135.25% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
7 | 5 | 8 | 7 | |
| 4.61% | 2.64% | 3.11% | 1.69% | ||
ROIC |
18.07% | 16.85% | 15.96% | 9.34% | |
Return on Tangible Assets |
(288.01%) | (124.65%) | (48.68%) | (43.73%) | |
Average Days of Receivables |
78.37 | 72.51 | 75.13 | 78.14 | |
Free Cash Flow per Share |
10.29 | 11.29 | 10.07 | 11.13 | |
Free Cash Flow |
18,210.00 | 19,980.00 | 17,816.00 | 19,684.00 | |
Capital Expenditures |
(1,297.00) | (1,244.00) | (1,214.00) | (1,176.00) | |
| Other line items | |||||
Cash ROIC |
25.47% | 26.42% | 25.64% | 27.41% | |
Accounts Receivable Turnover |
4.87 | 5.03 | 5.20 | 4.92 | |
Accounts Payable Turnover |
0.56 | 0.57 | 0.55 | 0.56 | |
Inventory Turnover |
3.64 | 3.85 | 3.99 | 3.84 | |
Average Days of Payables |
661.85 | 669.25 | 696.44 | 679.91 | |
Days of Inventory on Hand |
101.90 | 100.05 | 99.27 | 99.87 | |
Tax Rate |
(0.27) | (0.39) | (0.36) | 0.44 | |
Research and Development Expense of Revenue |
15.09% | 15.12% | 14.87% | 22.28% | |
Selling, General and Administrative Expense of Revenue |
22.79% | 22.76% | 22.91% | 23.42% | |
Share Based Compensation of Revenue |
1.52% | 1.57% | 1.56% | 1.61% | |
Interest Coverage |
6.38 | 5.80 | 5.74 | 3.50 | |
Operating CF/Net income |
3.11 | 5.90 | 4.55 | 8.88 | |
Depreciation/Fixed assets |
1.50 | 1.56 | 1.60 | 2.48 | |
Capex/Depreciation |
(0.15) | (0.14) | (0.14) | (0.09) | |
Revenue per Share |
36.40 | 35.49 | 34.57 | 33.72 | |
Operating CF per Share |
11.03 | 11.99 | 10.76 | 11.79 | |
Capex per Share |
(0.73) | (0.70) | (0.69) | (0.66) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 |
Columns are period end dates